Explore how Dentsply's (XRAY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
DENTSPLY SIRONA shares drop as Q3 earnings miss estimates and 2025 EPS guidance is cut amid segment weakness.
DENTSPLY SIRONA Inc. ( XRAY ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Wade Moody Daniel Scavilla - President, CEO & Director Conference Call Participants Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division David Saxon - Needham & Company, LLC, Research Division Jordan Bernstein - Stifel, Nicolaus & Company, Incorporated, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Erin Wilson Wright - Morgan Stanley, Research Division Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Ahmed Muhammad Rahat - Leerink Partners LLC, Research Division Michael Sarcone - Jefferies LLC, Research Division Allen Lutz - BofA Securities, Research Division Brandon Vazquez - William Blair & Company L.L.C.
The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Dentsply Sirona's Q3 results may reveal ongoing softness in U.S. demand and orthodontic segments despite steady cost control.
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Daniel Scavilla - President, CEO & Director Matthew Garth - Executive VP & CFO Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Good afternoon, everyone. My name is Erin Wright, the health care services analyst at Morgan Stanley.
Investors need to pay close attention to XRAY stock based on the movements in the options market lately.
XRAY's EDS and Wellspect are the key to stabilizing their results going forward. OIS and CTS continue to decline, but SureSmile grows in Europe. Their new CEO will also prioritize execution, rather than reinventing XRAY. They'll double down on integrated digital workflows and better customer experience. If they build a stickier ecosystem, I think XRAY does have the potential for a turnaround.
Explore Dentsply's (XRAY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Q2 2025 Earnings Call August 7, 2025 8:30 AM ET Company Participants Andrea Daley - Vice President of Investor Relations Daniel T. Scavilla - President, CEO & Director Matthew E.